NVCR
NovoCure Ltd

7,432
Loading...
Loading...
News
all
press releases
NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer
NovoCure submits a PMA to the FDA for TTFields therapy in pancreatic cancer, aiming to expand its oncology reach.
Zacks·25d ago
News Placeholder
More News
News Placeholder
NovoCure (NVCR) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for NovoCure (NVCR) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·2mo ago
News Placeholder
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of +7.69% and +3.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?
NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·3mo ago
News Placeholder
What Makes NovoCure (NVCR) a New Buy Stock
Zacks·3mo ago
News Placeholder
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial
Zacks·3mo ago
News Placeholder
Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect?
Zacks·4mo ago
News Placeholder
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working to...
Business Wire·8mo ago
News Placeholder
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
Novocure (NASDAQ: NVCR) announced today that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Ashley Cordova, Chief Executive Officer...
Business Wire·9mo ago
News Placeholder
Novocure Stock Soars On Positive Pancreatic Cancer Trial Results, Retail Sentiment Surges
The trial met its primary endpoint, showing a statistically significant improvement in median overall survival.
Stocktwits·10mo ago

Latest NVCR News

View

Advertisement. Remove ads.

Advertisement. Remove ads.